Clinical pharmacology and pharmacokinetics of amprenavir

Annals of Pharmacotherapy

Volumn 36, Issue 1, 2002, Pages 102-118

  Sadler, Brian M ^a   Stein, Daniel S ^b  

^a PHARSIGHT CORPORATION   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Amprenavir; HIV AIDS; Protease inhibitor

Indexed keywords

AMIODARONE; AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIMIGRAINE AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; HYPOCHOLESTEROLEMIC AGENT; INDINAVIR; LIDOCAINE; LOPINAVIR; NELFINAVIR; PROKINETIC AGENT; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; SAQUINAVIR; SILDENAFIL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ADULT; CHILD; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IC 50; MEDLINE; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

CARBAMATES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 0036140555     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10423     Document Type: Review

References (109)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. HTLV-III gag protein is processed in yeast cells by the virus polprotease
3. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor
4. Active immunodeficiency virus protease is required for viral infectivity
5. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases
6. Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A
7. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
8. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
9. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
10. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
11. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
12. HIV-protease inhibitors
13. In vitro activity of 141W94 (VX-478) in combination with other antiretroviral agents
14. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers
15. Pharmacokinetic modeling and simulations of the interaction of amprenavir and ritonavir
16. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor, amprenavir, after multiple, oral dosing
17. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
18. Single-dose safety and pharmacokinetics of amprenavir (141W94), an HIV-1 protease inhibitor in children
19. 1-acid glycoprotein on the pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor
20. 14C-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered in a single oral dose to healthy male subjects
21. Single-dose pharmacokinetics of indinavir and the effect of food
22. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343
23. Effect of timing of food and gastric pH on exposure to Ro31-8959, HIV proteinase inhibitor in healthy subjects
24. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
25. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
26. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs and humans
27. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
28. Drug binding to human alpha-1-acid glycoprotein in health and disease
29. 1-Acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)
30. Plasma protein binding displacement interactions - Why are they still regarded as clinically important?
31. Influence of race or ethnicity on pharmacokinetics of drugs
32. Antiviral activity and pharmacokinetics of amprenavir with or without zidovudine/3TC in the cerebral spinal fluid of HIV-infected adults
33. Antiviral activity of amprenavir in combination with zidovudine/3TC in plasma and CSF in patients with HIV-1 infection
34. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
35. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
36. Interaction of anti-HIV proteinase inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
37. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
38. Pharmacokinetics of saquinavir at steady state in CSF and plasma: Correlation between plasma and CSF viral load in patients on saquinavir containing regimens
39. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex
40. Levels of serum and cerebrospinal (CSF) indinavir (IDV) and HIV RNA in HIV-infected individuals
41. Analysis of amprenavir (APV)/3TC/ZDV in blood and seminal plasma: Penetration of APV into the male genital tract
42. Viral load and heterosexual transmission of human immunodeficiency virus type 1
43. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group protocol 850)
44. Cytochrome P-450 isozymes induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94
45. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
46. Nelfinavir mesylate: A protease inhibitor
47. Overview of the in vitro and in vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor
48. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
49. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9
50. 14C-141W94 (VX-478), an HIV-1 protease inhibitor
51. 14C]-amprenavir in rats
52. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers
53. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans
54. Single-dose pharmacokinetics of amprenavir, an HIV-1 protease inhibitor, in subjects with normal and impaired hepatic function
55. Plasma alpha 1-acid glycoprotein is reduced in HIV-infected subjects co-infected with hepatitis C virus (HCV)
56. Drug interactions in patients infected with human immunodeficiency virus
57. Drug interactions and adverse interactions with protease inhibitors
58. Update: Clinically significant cytochrome P-450 drug interactions
59. Pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of methadone (MD) enantiomers following co-administration with amprenavir (APV) in opioid-dependent subjects
60. The single-dose pharmacokinetics of 141W94, zidovudine and lamivudine when administered alone and in two- and three-drug combinations
61. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
62. Delavirdine significantly increases plasma concentrations of amprenavir in healthy volunteers
63. A pharmacokinetic study of HIV protease inhibitors used in combination with amprenavir
64. Pharmacokinetic interaction between amprenavir and rifabutin and rifampin in healthy males
65. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men
66. Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV-in fected patients
67. Drug interactions of HIV protease inhibitors
68. A randomized, placebo-controlled trial of saquinavir (SQV), indinavir (IDV), nelfinavir (NFV) in combination with amprenavir (APV), abacavir (ABC), efavirenz (EFZ) & adefovir (ADV) in patients (Pts) with protease inhibitor (PI) failure
69. The addition of a second protease inhibitor eliminates amprenavirefavirenz drug interactions and increases plasma amprenavir concentrations
70. Amprenavir (APV) plasma concentrations are dramatically increased by association to ritonavir (RTV) baby-doses in HIV-infected patients: Possible combination with efavirenz (EFV)
71. A Phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir
72. Interaction of ABT-378/ritonavir with protease inhibitors in healthy volunteers
73. Amprenavir plasma concentrations are dramatically decreased by association with ABT-378/ritonavir in HIV-infected patients
74. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
75. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
76. Ampren-avir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naïfve HIV-1 infected adults over 12 weeks (APV20001)
77. Rifampin and rifabutin and their metabolism by human liver esterases
78. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin
79. Prevention and treatment of tuberculosis among patients infected with the human immunodeficiency virus: Principles of therapy and revised recommendations
80. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
81. Discovery of VX-175/GW433908, a novel, water soluble prodrug of amprenavir
82. Food effect on single-dose safety and pharmacokinetics of GW433908, a prodrug of amprenavir (141W94, APV) administered as a tablet to healthy male study participants
83. Highly polar, water-soluble prodrugs of amprenavir: A new approach toward a more compact dosing regimen
84. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
85. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
86. Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
87. Indinavir concentrations and antiviral effect
88. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
89. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
90. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults
91. PK/PD analysis of variables that influence antiviral response in children treated with combination antiviral therapy
92. Evolution of resistance to the HIV protease inhibitor amprenavir: In vitro and in clinical studies. A review
93. Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance
94. High plasma trough levels favour selection of the 150V mutation pathway during development of amprenavir resistance